How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

382. The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro (PubMed)

, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro. Here we report the functional characterization of a third polymerase mutation (rtV173L) associated with resistance to lamivudine and famciclovir. rtV173L was observed at baseline in 9 to 22% of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV. In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M

Full Text available with Trip Pro

2003 Journal of virology

383. HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection (PubMed)

HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection We report two Chinese patients in whom lamivudine treatment resulted in HBsAg seroclearance. One patient received lamivudine, and another patient received 12-week famciclovir treatment followed by lamivudine. Lamivudine was maintained after HBeAg seroconversion. These two patients lost HBsAg at 24 and 27 months (ages, 23 and 19.3 years, respectively) and developed measurable titer

Full Text available with Trip Pro

2004 Journal of clinical microbiology

384. Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B

demonstrating potential anti-HBV activity other than lamivudine within the previous 3 months (e.g. famciclovir, lobucavir, emtricitabine, DAPD, L-FMAU, entecavir, ganciclovir or others). History of hypersensitivity to nucleoside and/or nucleotide analogues. Clinical, ultrasonographic or radiologic evidence of hepatic mass suggestive of hepatocellular carcinoma. Serum alphafetoprotein (AFP) > 50 ng/mL at the first screening visit. However, if the AFP level is > 50 ng/mL at the first screening visit, but has

2006 Clinical Trials

385. VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

treatments (e.g., valacyclovir, acyclovir, ganciclovir, famciclovir) within 3 days of starting study drug, or immunomodulatory treatments in the 30 days before starting study drug. Subject has clinically significantly impaired renal function as defined by creatinine clearance less than 50ml/min (calculated using the Cockcroft-Gault formula). Subjects with a history or evidence of decompensated liver disease, or clinically significantly impaired hepatic function defined as an ALT (alanine transaminase (...) ) level >3 times the normal upper limit. Subject is known to be hypersensitive to valacyclovir, acyclovir, ganciclovir or famciclovir. Subject has malabsorption or vomiting syndrome or other gastrointestinal dysfunction that may impair drug pharmacokinetics. Female subject who is contemplating pregnancy within the duration of the study drug dosing period. Female subject who is pregnant and/or nursing. Subject with current alcohol or drug abuse. Subjects who have received suppressive (daily) therapy

2006 Clinical Trials

386. Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

study has been proposed because it has become clear there are marked limitations to the benefit of antiviral therapy in herpes labialis. Recently, a pilot trial of the combination of famciclovir and topical 0.05% fluocinonide vs famciclovir alone showed that the addition of corticosteroids to the antiviral drug treatment caused a marked and statistically significant reduction in lesion size and a trend to more aborted lesions. This study is designed as a randomized, placebo-controlled, , patient

2006 Clinical Trials

387. Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patient With Chronic HBV

with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Previous treatment with interferon that had ended less than 6 months prior to the screening visit. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients co-infected with HCV, HDV or HIV. Patients with clinical evidence of liver mass or with alpha-fetoprotein > 50 ng/mL Patients who were pregnant or breast-feeding. Patients who were unwilling to use an "effective

2006 Clinical Trials

388. Safety and Antiviral Activity Study of Clevudine 30 Mg QD in Patients With HBeAg(-) Chronic HBV

therapy. Patients previously treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Previous treatment with interferon that had ended less than 6 months prior to the screening visit. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients coinfected with HCV, HDV or HIV. Patients with clinical evidence of liver mass or with alfa-fetoprotein > 50 ng/mL Patients who were pregnant or breast-feeding. Patients

2006 Clinical Trials

389. Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

)experienced a >= 1 log10 decrease from baseline in HBV DNA at Week 48 Exclusion Criteria: Patient with HBeAg seroconverted to anti-HBe at the last 2 consecutive visits (one month apart) in L-FMAU-201 study. Patient who was currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patient who was treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection after cessation of treatment in L-FMAU-201 study. Patient who had a history

2006 Clinical Trials

390. Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis

or 3 months or more after completion of any antiviral treatment (eg. famciclovir, lamivudine etc.), and the patient has not had interferon therapy or any antiviral therapy between the biopsy and screening. Liver biopsy showing advance fibrosis/cirrhosis (Ishak fibrosis score ≥4). The slides must be available for review by an independent histopathologist. Availability and willingness of the subject to provide written informed consent per ICH/GCP and local Guidelines. Exclusion Criteria: ALT >10XULN

2006 Clinical Trials

391. Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

of reference range Serum creatinine >1.5 times upper limit of reference range Haemoglobin < 11g/dL WBC count <3x10^9/L Platelets <100x10^9 Serious concurrent medical illness other than hepatitis B Use of immunosuppressive therapy, immunomodylatory therapy or chronic antiviral thgerpay with other agents within the previous 6 months or during the study Previous treatment with lamivudine or famciclovir within the last 6 months History of hypersensitivity to nucleoside analogues Women of childbearing potential

2006 Clinical Trials

392. Suppression of Oral HHV8 Shedding With Valganciclovir

drugs with known anti-HHV-8 activity for study duration able to comply with the study protocol agree to HIV testing Exclusion Criteria: history of evidence of CMV disease hypersensitivity to ganciclovir or valganciclovir use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or cidofovir neutropenia renal insufficiency with serum creatinine greater than 1.5mg.ml or CrCl less than 60 AST or ALT greater than 5 times upper limit of normal concurrent administration of medications

2005 Clinical Trials

393. Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon

criteria are not eligible for this study. Known history of adverse reaction to acyclovir Planned open label use of acyclovir, valacyclovir, or famciclovir Positive pregnancy test Active opportunistic infection Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2005 Clinical Trials

394. Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients

: Novartis Information provided by: Novartis Study Details Study Description Go to Brief Summary: This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes Condition or disease Intervention/treatment Phase Genital Herpes Drug: Famciclovir Drug: Placebo Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 463 participants Allocation: Randomized (...) Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients Study Start Date : June 2007 Actual Primary Completion Date : March 2009 Actual Study Completion Date : March 2009 Resource

2007 Clinical Trials

395. HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

-confirmed asymptomatic gonorrhea and syphilis) are treated within two weeks of study enrollment and random assignment. Exclusion Criteria: Women who meet any of the following criteria are not eligible for this study: Known history of adverse reaction to valacyclovir, acyclovir or famciclovir; Planned open label use of acyclovir, valacyclovir, or famciclovir Known medical history of seizures Known renal failure, serum creatinine >2.0mg/dl Hematocrit < 30 % Contacts and Locations Go to Information from

2007 Clinical Trials

396. Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

clinical evaluations Willing and able to take study drug as directed Willing and able to adhere to follow-up schedule Exclusion Criteria: Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir Planned open label use of acyclovir, valacyclovir, or famciclovir History of evidence of CMV disease Known medical history of seizures Known renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl AST or ALT greater than 3 times upper limit of normal Hematocrit less than 30

2007 Clinical Trials

397. To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)

that a barrier method of contraception be used (i.e. condom with spermicide or diaphragm with spermicide) by patients of childbearing potential (men and women) regardless of whether a hormonal agent also is used as a method of contraception; Patient is co infected with hepatitis C virus (HCV), HIV. Patients will be tested for antibodies to HCV & HIV in the Screening assessments;Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir; Patient is currently

2007 Clinical Trials

398. Scandinavian Bell's Palsy Study

women not employing acceptable methods of contraception and/or women planning to become pregnant during the period with intake of study medication. Subjects with a history of immunodeficiency syndromes. Subjects with an allergy or sensitivity to aciclovir or valaciclovir, famciclovir or ganciclovir. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2007 Clinical Trials

399. Effect of HSV-2 Suppressive Therapy on Sexual Behavior

with the study protocol Exclusion Criteria: Pregnancy or intention to become pregnant within the next year Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of enrollment/randomization 6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months prior to starting suppressive therapy if on suppressive therapy during the prior 12 months HIV seropositive or known immunocompromising medical condition. HIV negative test must be performed within 60 days of Visit

2007 Clinical Trials

400. Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

(except for systemic acyclovir, valacyclovir and famciclovir), cytotoxic drugs, investigational drugs, or any drugs known to have major organ toxicity. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00189293 Locations Layout table for location

2005 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>